share_log

Ladenburg Thalmann Initiates Coverage On Nuvectis Pharma with Buy Rating, Announces Price Target of $21

Benzinga Real-time News ·  Jul 13, 2022 08:38

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Buy rating and announces Price Target of $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment